Effect of therapeutic erythrocytapheresis on outcomes and renal benefit in patients with high-altitude polycythemia: a real-world study Authors: Yan Ouyang, Yinyin Zhang, Huan Li, Luo Bu Zhuo Ma, Ci Ren De Ji, Chunyan Qiao, Ba Dun, Xiaodong Gao, Jun Zhu, Pengpeng Xu, Yu Zheng, Xiaoyang Li, Jianhua You, Chuanhe Jiang, Fei Yue, Junmin Li, Pu Bu Wang Dui, Kai Xue, Kai Qing Published: 2024 ABSTRACT AbstractKidney injury from high-altitude polycythemia (HAPC) is common, yet few studies have explored effective treatments. This research assessed the renal benefits of therapeutic erythrocytapheresis (TE) in HAPC patients, analyzing the efficacy of single versus multiple treatments. From 2017 to 2023, 631 patients undergoing TE were included. Findings showed notable improvements in hemoglobin levels (median: 228.00 vs. 169.00 g/L, p < 0.001), estimated glomerular filtration rate (eGFR) (median: 100.24 vs. 105.92 ml/min/1.73 m2, p < 0.001), and uric acid levels (median 495.00 vs. 405.00 µmol/L, p < 0.001). The rate of patients with negative urine protein tests rose from 54.58 to 92.83%. Analysis indicated that a lower pre-treatment eGFR was associated with significant renal improvement post-treatment (OR 0.959, 95% CI 0.945–0.972, p < 0.001), even when adjusting for hemoglobin and other factors (OR 0.962, 95% CI 0.947–0.977, p < 0.001). After propensity score matching, 168 patients were categorized based on the number of treatments. Compared to single treatment, multiple treatments resulted in significantly lower hemoglobin levels post-treatment (median: 177.00 vs. 165.00 g/L, p < 0.001). TE proves to be a beneficial treatment for HAPC, improving hemoglobin and renal function. Multiple treatments may be preferable for maintaining stable hemoglobin levels.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-024-80609-6.Keywords: High-altitude polycythemia, Therapeutic erythrocytapheresis, Renal benefits, Multiple treatmentsSubject terms: Haematological diseases, Translational research, Kidney Introduction High-altitude polycythemia (HAPC) is one of the most prevalent and severe chronic altitude-related diseases and is associated with a significant risk of mortality in advanced stages. Its prevalence ranges from 5 to 18%, making it a major public health concern. HAPC is defined as a hemoglobin level exceeding 190 g/L in females and 210 g/L in males1. A condition resulting from prolonged exposure to high-altitude environments, HAPC primarily stems from a compensatory response to hypoxia, with the kidney being one of the most severely affected organs2,3. Elevated uric acid levels and urine protein are common among HAPC patients, and renal dysfunction can progress to renal failure in later stages4–7. In recent years, only a few studies have focused on renal injury in HAPC patients. A case report of renal biopsy confirming glomerular abnormalities associated with HAPC has been published, and a cohort study by Wang et al.8 in 2022 proposed that pathological changes related to renal injury in HAPC, including glomerular and renal artery/arteriole lesions, chronic hypoxia itself and secondary hemodynamic changes, play crucial roles in the pathogenesis of this disease. Early and effective intervention and treatment are crucial for slowing disease progression and avoiding increased medical burdens. Therefore, the treatment of HAPC is highly important. Traditional treatment methods have limitations; for example, phlebotomy is effective in the short term but may lead to rebound exacerbation in the long term, along with the loss of white blood cells and platelets9, whereas drug therapy requires intensive monitoring and timely medication adjustment10. Therapeutic erythrocytapheresis (TE)11, also known as blood separation therapy, was introduced at Shigatse People’s Hospital in Tibet in 201612. This technique removes excessive red blood cells from the blood while preserving normal components such as white blood cells and platelets to improve blood viscosity and hypoxic conditions. It was initially proposed for the treatment of HAPC and gradually applied in clinical practice. Despite having a theoretical basis and clinical prospects, the evidence regarding the renoprotective effects of TE in HAPC patients is limited. Therefore, we performed a real-world study to explore the efficacy and renal benefits of TE in treating HAPC patients. Results Baseline characteristics of the whole cohort A total of 631 patients were enrolled according to the inclusion criteria (Fig. 1). The majority of patients were male (95.09%). The median age was 48 years, and the predominant ethnicity was Tibetan (86.37%). The median glucose level was 4.50 mmol/L; the median glycated hemoglobin level was 6.20%; the mean arterial pressure (MAP) was 101.33mmHg; and the median alanine aminotransferase and aspartate aminotransferase levels were 38.00 IU/L and 27.00 IU/L, respectively. The median total bilirubin level was 23.30 µmol/L, and the median direct bilirubin level was 17.70 µmol/L. Regarding renal function, 71.78% of patients had an eGFR ≥ 90 ml/min/1.73 m2, 25.78% had an eGFR between 60 and 89 ml/min/1.73 m2, and 2.43% had an eGFR < 60 ml/min/1.73 m2. Approximately 40.10% of patients were found to have proteinuria, while 75.08% had hyperuricemia (Table 1). Flow diagram of cohort participant inclusion. HAPC, High Altitude Polycythemia; eGFR, estimated glomerular filtration rate. Table 1Baseline clinical characteristics of the whole cohort.CharacteristicThe whole cohortN = 631Age (years), median (IQR)48.00 (39.00, 57.00)Male sex, n (%)600 (95.09%)Race, n (%) Tibetan545 (86.37%) Han86 (13.63%) Proteinuria, n(%)239 (40.10%) Hyperuricemia, n(%)449 (75.08%)eGFR levels, ml/min/1.73m2 ≥ 90412 (71.78%) 60–89148 (25.78%) 30–5913 (2.26%) 15–291 (0.17)Mean arterial pressure (mmHg), median (IQR)101.33 (93.33, 111.33)Glucose (mmol/L), median (IQR)4.50 (3.98, 5.09)Glycated hemoglobin (%), median (IQR)6.20 (5.60, 6.70)Alanine aminotransferase (IU/L), median (IQR)38.00 (24.00, 56.00)Aspartate aminotransferase (IU/L)), median (IQR)27.00 (21.00, 36.50)Total bilirubin (µmol/L), median (IQR)23.30 (16.70, 32.60)Direct bilirubin (µmol/L), median (IQR)17.70 (12.60, 24.70)eGFR, Estimated Glomerular Filtration Rate.Baseline Proteinuria missing 35 cases; urine acid missing 33 cases; eGFR missing 57 cases. Baseline clinical characteristics of the whole cohort. eGFR, Estimated Glomerular Filtration Rate. Baseline Proteinuria missing 35 cases; urine acid missing 33 cases; eGFR missing 57 cases. Comparison of improvement in hematologic indicators after TE The improvements in hematologic parameters after treatment were compared in 631 patients. Red blood cell count (median: 7.27 vs. 5.47 *1012/L, p < 0.001), hemoglobin (median: 228.00 vs. 169.00 g/L, p < 0.001), mean arterial pressure (median:101.33 vs. 89.67 mmHg, p < 0.001) and hematocrit (median: 68.60 vs. 51.90%, p < 0.001) all demonstrated significant decreases after treatment. However, there was no significant improvement in white blood cell count, while the platelet count increased (median: 145.00 vs. 163.00 *109/L, p < 0.001). Subsequently, when comparing procoagulant indicators, prothrombin time (median: 11.60 vs. 10.80 s, p < 0.001), activated partial thromboplastin time (median: 40.20 vs. 32.30 s, p < 0.001), and thrombin time (median: 19.20 vs. 17.80 s, p < 0.001) were significantly shorter. D-dimer levels (median: 0.24 vs. 0.27 mg/ml, p = 0.002) significantly increased after treatment but remained within the normal range. There were no significant changes in fibrinogen or fibrin degradation products after treatment (Table 2). Table 2Comparation of clinical characteristics between pre-treatment and after treatment(n = 631).CharacteristicsPre-treatment, N = 631After treatment, N = 631p valueRed blood cell (1012/L), median (IQR)7.27 (6.75, 7.81)5.47 (5.08, 5.99) < 0.001 Hemoglobin (g/L), median (IQR)228.00 (213.00, 241.00)169.00 (160.00, 179.00) < 0.001 Hematocrit (%), median (IQR)68.60 (63.55, 72.60)51.90 (48.55, 55.65) < 0.001 Platelet (109/L), median (IQR)145.00 (116.00, 178.00)163.00 (133.00, 196.00) < 0.001 Prothrombin time (s), median (IQR)11.60 (10.70, 12.90)10.80 (10.10, 11.40) < 0.001 International normalized ratio, median (IQR)1.02 (0.93, 1.12)0.95 (0.87, 1.03) < 0.001 Activated partial thromboplastin time (s), median (IQR)40.20 (32.65, 47.65)32.30 (28.10, 36.40) < 0.001 Fibrinogen (g/L), median (IQR)2.41 (1.99, 2.95)2.37 (1.99, 2.88)0.285Thrombin time (s), median (IQR)19.20 (17.85, 20.60)17.80 (16.60, 18.85) < 0.001 D-dimer (mg/ml), median (IQR)0.24 (0.19, 0.33)0.27 (0.19, 0.42) 0.002 Fibrin degradation products (µg/ml), median (IQR)0.99 (0.78, 1.39)0.98 (0.76, 1.30)0.362Mean arterial pressure (mmHg), median (IQR)101.33 (93.33, 111.33)89.67 (82.00, 97.33) < 0.001 Blood urea nitrogen (mg/dl), median (IQR)3.88 (3.20, 4.83)3.53 (2.82, 4.30) < 0.001 eGFR (ml/min/1.73m2), median (IQR)100.24 (88.55, 110.12)105.92 (96.33, 114.53) < 0.001 Urinary total protein catalog, n(%) < 0.001 Negative137 (54.58%)233 (92.83%) 0.5+28 (11.16%)1 (0.40%) 1+39 (15.54%)12 (4.78%) 2+38 (15.14%)5 (1.99%) 3+8 (3.19%)0 (0.00%) 4+1 (0.40%)0 (0.00%)Uric acid (µmol/L), median (IQR)495.00 (435.25, 582.75)405.00 (342.00, 457.75) < 0.001 eGFR, Estimated Glomerular Filtration Rate.Before and after treatment, there were only 251 cases with simultaneous records of urinary protein. Comparation of clinical characteristics between pre-treatment and after treatment(n = 631). eGFR, Estimated Glomerular Filtration Rate. Before and after treatment, there were only 251 cases with simultaneous records of urinary protein. According to the linear regression analysis assessing the impact of different parameters on the rate of hemoglobin decrease, univariate analysis revealed that age, hemoglobin level, red blood cell count, hematocrit, prothrombin time, activated partial thromboplastin time, thrombin time and eGFR were significantly associated with the rate of hemoglobin decrease. Multivariate analysis confirmed that advanced age, higher hemoglobin levels, and longer total clotting time were significantly associated with the rate of hemoglobin decrease. No significant association was found between the eGFR and the rate of hemoglobin decrease. Specifically, in elderly patients, with each year increase in age, the rate of hemoglobin decrease lowered by 0.070 g/L (95% CI: −0.120, − 0.021; p = 0.006); for each 1 g/L increase in hemoglobin level, the rate of hemoglobin decrease increased by 0.217 g/L (95% CI: 0.160, 0.273; p < 0.001); and for each second increase in total clotting time, the rate of hemoglobin decrease lowered by 0.389 g/L (95% CI: −0.714, − 0.063; p = 0.019). These findings suggest that the rate of hemoglobin decrease is more profoundly influenced by advanced age, higher hemoglobin levels, and longer total clotting time (Supplementary Table S1). Therapeutic effects on renal indicators and renal protection After treatment, there was a significant improvement in blood urea nitrogen (3.88 vs. 3.53 mg/dL, p < 0.001), eGFR (100.24 vs. 105.92 ml/min/1.73 m2, p < 0.001), and uric acid (495.00 vs. 405.00 µmol/L, p < 0.001). Additionally, the rate of patients with negative urine protein tests rose from 54.58 to 92.83% after TE (Table 2). A logistic regression model was used to analyze the improvement in eGFR as the outcome variable. Univariate analysis revealed a significant negative correlation between pretreatment eGFR and improvement in eGFR post-treatment [odds ratio (OR) = 0.959, 95% confidence interval (CI): 0.945–0.972, p < 0.001]. These findings suggest that patients with lower pretreatment eGFRs are more likely to experience improved eGFRs post-treatment. After multivariate analysis adjusted for clinical parameters including hemoglobin, coagulation indicators, blood urea nitrogen and uric acid, this association persisted (OR = 0.962, 95% CI = 0.947–0.977, p < 0.001). Therefore, pretreatment eGFR is an independent predictor closely associated with improvement in eGFR post-treatment. Similar results were also observed regarding serum uric acid levels. In the multivariate analysis, pretreatment levels of uric acid were significantly associated with an improvement in eGFR after TE treatment (OR = 1.003, 95% CI = 1.001–1.005; p = 0.017). This finding suggests that uric acid levels may be related to renal injury, and their reduction contributes to the enhancement of eGFR. Additionally, higher pretreatment hemoglobin and hematocrit levels, prothrombin times, international normalized ratios, activated partial thromboplastin times and blood urea nitrogen levels were shown to be associated with improved eGFRs in univariate analysis. However, these associations did not reach statistical significance in the multivariate analysis (Table 3). Table 3Logistic regression analysis of the effect of each parameter on the improvement in eGFR (n = 631).CharacteristicsUni-variateMulti-variateOR95% CIp valueOR95% CIp valueGender (male)1.5830.686, 3.5690.27Age (years)1.0090.992, 1.0270.309Mean arterial pressure (mmHg)0.9970.983, 1.0120.71Red blood cell (1012/L)1.1440.900, 1.4600.275Hemoglobin (g/L)1.0131.002, 1.025 0.022 1.0170.995, 1.0390.124Hematocrit (%)1.0371.001, 1.075 0.045 0.9780.910, 1.0510.544Platelets (109/L)0.9960.992, 1.0000.066Prothrombin time(s)1.1591.037, 1.308 0.013 1.1760.625, 2.4210.632International normalized ratio4.9321.404, 19.258 0.017 0.1690.000, 210.8330.634Activated partial thromboplastin time (s)1.0171.002, 1.034 0.036 1.0120.989, 1.0380.315Fibrinogen (g/L)0.9750.770, 1.2420.838Thrombin time (s)1.1261.010, 1.259 0.034 0.9780.848, 1.1240.751D-dimer (mg/ml)1.8481.031, 4.3560.098Fibrin degradation products (µg/ml)1.1630.995, 1.4570.127Blood urea nitrogen (mg/dl)1.2691.089, 1.493 0.003 1.0690.895, 1.2870.468eGFR (ml/min/1.73m2)0.9590.945, 0.972 < 0.001 0.9620.947, 0.977 < 0.001 Urinary total protein > 2+2.0970.752, 7.4270.193Uric acid (µmol/L)1.0041.002, 1.006 < 0.001 1.0031.001, 1.005 0.017 eGFR, Estimated Glomerular Filtration Rate.Prothrombin Time and International Normalized Ratio have multicollinearity, so that only include one of them in the multivariable model. Logistic regression analysis of the effect of each parameter on the improvement in eGFR (n = 631). eGFR, Estimated Glomerular Filtration Rate. Prothrombin Time and International Normalized Ratio have multicollinearity, so that only include one of them in the multivariable model. Adverse events There were 32 cases of hypocalcemia (27 patients in the single treatment group and 5 patients in the multiple TE treatment group) and 8 cases of hypotension (7 patients in the single treatment group and 1 patient in the multiple treatment group), as well as 3 cases of allergy (all in the single TE treatment group). There were no significant differences in adverse events between the two groups, and overall adverse events were controllable with no particularly severe adverse events occurring. No splenomegaly, hypertension, cerebral infarction, itching, difficulty urinating, or infections were observed within 48 h after TE therapy. Comparison of efficacy between single and multiple TE therapy Analysis revealed significant differences in the absolute changes in hemoglobin levels among the different treatment groups: compared to 529 patients receiving only a single TE treatment (median absolute change in hemoglobin: −54.00 g/L; IQR: −63.00, − 43.00), the median absolute change in hemoglobin levels increased to − 80.00 g/L (IQR: −89.00 g/L, − 66.00 g/L; p < 0.001) in 98 patients receiving two TE treatments; in 4 patients receiving more than two TE treatments, the median absolute change in hemoglobin levels further increased to − 90.00 g/L (IQR: −94.25 g/L, − 70.25 g/L; p = 0.093, Fig. 2a). Hemoglobin reduction intensified with increased TE treatment frequency. In addition, out of the 631 enrolled patients, only 102 underwent multiple-time TE treatments. Of them, 75 underwent two TE sessions during the same hospitalization without requiring further treatment. The remaining 27 patients underwent multiple TE sessions across different hospitalizations, resulting in a total of 33 relapse events with a median relapse interval of 518 days (IQR, 391–741). Changes in Hb Levels with Different Treatment-time groups. (a) Absolute changes in Hb levels across various treatment times in the overall population. (b) Absolute changes in Hb levels with different treatment times among 168 patients after propensity score matching (PSM). ***, p < 0.001; ns, no significant. To assess the effect of multiple-time TE treatments on hemoglobin and kidneys compared to single-time TE treatment, we analyzed 168 patients after PSM based on gender, age, race, MAP and hemoglobin levels. The baseline clinical characteristic of patients included and excluded from PSM was showed in Supplementary Table S2. Baseline indicators, including hemoglobin, showed no statistically significant differences between the two TE groups (Supplementary Table S3). Compared to 84 patients receiving single-time TE treatment with a median absolute change in hemoglobin of − 61.00 g/L (IQR: −70.25, − 52.75), those 84 patients receiving multiple-time TE treatment showed an increase to − 76.00 g/L (IQR: −87.00 g/L, − 64.75 g/L; p < 0.001; Fig. 2b). Subsequently, we compared the differences in indicators before and after single-time and multiple-time TE treatments. The hemoglobin level showed only a slight decrease after single-time TE treatment, whereas it significantly decreased after multiple-time TE treatments (median: 177.00 vs. 165.00 g/L, p < 0.001, Table 4). Additionally, although there was a trend of improvement in eGFR after multiple-time TE treatments compared to single-time TE treatment, and an increase in the proportion of patients with 2 plus or higher urinary protein turning negative, these changes did not reach statistical significance (Table 4). Table 4Comparison of pre- and post-treatment indicators between single and multiple procedure after PSM.CharacteristicsOne-time procedure, N = 84Multiple procedure, N = 84Pre-treatmentAfter treatmentBaseline pre-treatment,Baseline after treatmentp valueaLast follow-up pre-treatment,Last follow-up after treatmentp value bRed blood cells (1012/L)7.48 (7.14, 7.99)5.50 (5.17, 6.04)7.77 (7.26, 8.20)5.76 (5.26, 6.31)0.157.08 (6.94, 7.66)5.66 (5.42, 5.84)0.41Hemoglobin (g/L)241.50 (234.25, 246.25)177.00 (170.00, 185.25)241.00 (232.00, 249.00)174.50 (165.00, 196.00)0.63204.00 (198.00, 220.00)165.00 (158.00, 172.00) < 0.001 Hematocrit (%)71.60 (68.90, 73.50)53.05 (50.90, 55.78)72.80 (69.72, 75.70)53.60 (50.60, 60.40)0.1867.40 (63.80, 69.20)52.40 (50.55, 54.05)0.53Platelets (109/L)131.00 (101.00, 158.50)154.00 (117.75, 189.00)136.00 (104.50, 159.00)155.50 (132.00, 197.75)0.28130.50 (118.00, 144.00)144.00 (124.50, 162.50)0.18Prothrombin time (s)12.00 (11.20, 13.00)11.00 (10.20, 11.53)12.30 (11.20, 13.50)11.00 (10.28, 11.30)0.7111.10 (10.60, 11.70)10.30 (9.95, 11.25)0.29International normalized ratio1.05 (0.97, 1.13)0.96 (0.88, 1.02)1.07 (0.99, 1.19)0.96 (0.88, 1.02)> 0.990.96 (0.92, 1.02)0.99 (0.89, 1.12)0.29Activated partial thromboplastin time (s)40.65 (34.30, 46.92)32.25 (27.37, 36.62)44.90 (37.20, 55.10)32.70 (29.85, 36.97)0.3835.10 (31.20, 39.20)33.50 (29.05, 36.00)0.77Fibrinogen (g/L)2.13 (1.79, 2.63)2.23 (1.93, 2.64)2.30 (1.91, 2.85)2.48 (2.11, 2.92)0.162.00 (1.79, 2.42)2.51 (2.04, 3.11)0.38Thrombin time (s)20.15 (18.95, 21.40)18.15 (17.38, 19.22)20.20 (19.00, 20.90)17.40 (16.40, 18.72)0.0519.30 (19.00, 20.00)17.70 (16.35, 19.50)0.63D-dimer (mg/ml)0.23 (0.19, 0.29)0.23 (0.19, 0.38)0.25 (0.20, 0.32)0.26 (0.19, 0.34)0.680.22 (0.20, 0.29)0.34 (0.21, 0.43)0.29Fibrin degradation products (µg/ml)0.99 (0.82, 1.21)0.88 (0.68, 1.06)0.94 (0.78, 1.24)0.99 (0.74, 1.31)0.130.99 (0.81, 1.21)1.00 (0.92, 1.48) 0.04 Mean arterial pressure (mmHg)100.83 (91.67, 110.50)88.00 (81.50, 95.17)101.00 (93.33, 111.58)89.67 (80.25, 102.17)0.41103.33 (96.83, 105.67)88.00 (83.33, 96.00)0.65Blood urea nitrogen (mg/dl)3.88 (3.26, 4.64)3.60 (2.82, 4.39)3.78 (3.07, 4.82)3.59 (2.65, 4.10)0.433.84 (3.64, 4.39)3.29 (2.95, 3.67)0.59eGFR (ml/min/1.73m2)100.20 (88.28, 107.67)109.23 (97.56, 116.10)106.13 (95.32, 114.87)111.83 (102.96, 120.26)0.0796.22 (86.03, 101.91)102.91 (93.44, 110.71)0.31Urinary total protein catalog0.16> 0.99 Negative43 (54.43%)27 (93.10%)38 (48.72%)42 (100.00%)14 (73.68%)9 (100.00%) 0.5+12 (15.19%)0 (0.00%)5 (6.41%)0 (0.00%)3 (15.79%)0 (0.00%) 1+12 (15.19%)2 (6.90%)21 (26.92%)0 (0.00%)1 (5.26%)0 (0.00%) 2+11 (13.92%)0 (0.00%)11 (14.10%)0 (0.00%)1 (5.26%)0 (0.00%) 3+1 (1.27%)0 (0.00%)3 (3.85%)0 (0.00%)0 (0.00%)0 (0.00%)Urinary acid (µmol/L)490.00 (433.50, 546.00)406.50 (347.00, 452.25)504.50 (422.50, 582.00)414.00 (353.00, 471.00)0.37420.00 (379.75, 483.75)423.50 (373.75, 457.00)0.64aP value is the first post-treatment of multiple treatments vs. the post-treatment for a single treatment.bP value is the last post-treatment of multiple treatments vs. the post-treatment for a single treatment. Comparison of pre- and post-treatment indicators between single and multiple procedure after PSM. aP value is the first post-treatment of multiple treatments vs. the post-treatment for a single treatment. bP value is the last post-treatment of multiple treatments vs. the post-treatment for a single treatment. Discussion To assess the effectiveness of TE therapy in HAPC patients and its effects on renal outcomes, a total of 631 patients, who were predominantly males and were mainly of Tibetan ethnicity, were enrolled in this study. After receiving a single treatment, patients demonstrated significant decreases in red blood cell count, hemoglobin, and hematocrit, while renal function parameters, including eGFR and uric acid, improved significantly. Moreover, the proportion of patients with negative urinary protein levels significantly increased. Further analysis revealed that, compared with the patients receiving a single TE treatment, the patients receiving multiple TE treatments exhibited more significant improvements in hematological parameters. Although the eGFR showed an increasing trend after multiple treatments, the difference compared with that of the group receiving a single treatment was not significant. In conclusion, this study revealed that a single TE treatment significantly improved hematological parameters and renal function in HAPC patients. Moreover, multiple TE treatments appeared to provide additional benefits by achieving greater reductions in hemoglobin levels, which may contribute to better stabilization of hemoglobin in these patients. Consistent with the findings of previous study12, we validate that red blood cell counts, hemoglobin levels, and hematocrit levels all significantly decreased after treatment, whereas white blood cell counts did not significantly improve, and platelet counts increased slightly. Linear regression analysis demonstrated significant associations between advanced age, high hemoglobin levels, prolonged clotting time and the rate of hemoglobin decrease. The literatures suggested that individuals with HAPC may be prone to microthrombosis due to increased blood viscosity, which leads to abnormal coagulation function and a tendency toward bleeding13,14. Our study revealed that prothrombin time, activated partial thromboplastin time, and thrombin time were significantly shorter after treatment, whereas D-dimer levels were significantly greater, indicating an improvement in the tendency toward bleeding after treatment. Several studies have explored potential mechanisms of kidney damage in HAPC patients15,16. High-altitude hypoxia upregulates renal HIF-2α expression, increasing erythropoietin production and causing polycythemia, which reduces renal plasma flow and raises blood viscosity17. To compensate, renal blood flow and GFR increase, leading to glomerular hyperfiltration and hypertrophy, causing podocyte injury due to mechanical stress. Chronic hypoxia, combined with factors like hypertension or hemodynamic changes, may also result in renal arterial damage16,18. Additionally, hyperuricemia, common at high altitudes and linked to proteinuria, may contribute to kidney damage19, as it is associated with glomerular hypertrophy and glomerulosclerosis20,21. Several researches have provided the possible mechanisms of kidney damage in HAPC patients. On the one hand, in a high-altitude hypoxic environment, renal expression of HIF-2a is upregulated, leading to increased production of erythropoietin and resulting in polycythemia17. This leads to a significant reduction in renal plasma flow and results in increased blood viscosity. To compensate for the reduced renal plasma flow, renal blood flow and the GFR increase, leading to glomerular hyperfiltration and hypertrophy, which in turn induces podocyte injury due to mechanical stress. On the other hand, chronic hypoxia exposure, possibly in conjunction with other factors such as hypertension or secondary hemodynamic changes18, might lead to pathological changes in renal arteries/arterioles. Additionally, hyperuricemia might be associated with HAPC-related kidney damage19. Hyperuricemia is common in populations living at high altitudes and is associated with proteinuria. Rats with hyperuricemia have been found to develop glomerular hypertrophy and eventually glomerulosclerosis20,21. These findings suggest that hyperuricemia may be another contributing factor to HAPC-related kidney disease. TE therapy effectively removes excessive red blood cells from patients, which in turn reduces blood viscosity and helps to maintain normal glomerular filtration function22. Hypoxia, one of the main causes of HAPC in high-altitude environments, also affects the kidneys, which are particularly sensitive to hypoxia because of their high oxygen demands23. TE treatment can improve systemic hemodynamics, increase oxygen delivery, alleviate renal hypoxia, therefore might protect renal function. Furthermore, our research results confirmed that HAPC patients experience significant improvement in renal function after TE treatment. Logistic regression analysis indicated that patients who had lower pretreatment eGFR being more likely to experience eGFR improvement after treatment. Additionally, blood uric acid levels were associated with improved eGFR, suggesting that uric acid may play a role in this process. These findings provide strong clinical support for the renal benefits of TE therapy in HAPC patients. According to previous researches, therapeutic erythrocytapheresis (TE) presents potential advantages over traditional phlebotomy in reducing certain risks. In secondary erythrocytosis conditions like HAPC or cardiopulmonary diseases, hypoxia is often the primary cause. For instance, erythrocytosis due to cardiopulmonary disease is a compensatory response to hypoxia, and reducing red blood cell count through phlebotomy may worsen hypoxia. Thus, treating secondary erythrocytosis should target the underlying cause, making routine phlebotomy not recommended24. Despite its efficacy, phlebotomy is costly, inconvenient, and can hinder patient adherence25. While TE therapy12 has been shown to have efficacy in patients with HAPC, research on multiple treatments is relatively limited. Our study revealed that, compared with patients receiving a single treatment, patients in the multiple treatment group exhibited a more significant reduction in hemoglobin levels. To mitigate the impact of confounding factors, we conducted PSM. The results showed that the multiple treatment group demonstrated a more pronounced decrease in hemoglobin and a lower increase in platelets than did the single treatment group. Although the number of patients in the renal function analysis was small (a total of 28 patients with renal function parameters before and after multiple treatments), the difference between the two groups did not reach statistical significance. However, there was a decrease in the proportion of patients with urine protein after treatment. This could be attributed to the ability of multiple treatments to sustainably reduce blood viscosity and red blood cell count, thereby improving hemorheological properties, reducing renal burden, and better alleviating patient symptoms. Furthermore, under intensive monitoring, multiple treatments did not increase the incidence of adverse events, including possible adverse reactions such as hypocalcemia. This study represents the largest cohort study of HAPC patients worldwide to date, and it has several highlights. These findings confirm the effectiveness of TE therapy in improving hemoglobin levels in HAPC patients and provide an effective treatment option. The study also revealed that this treatment has a protective effect on renal function, particularly through improving kidney function and reducing uric acid levels. Further analysis revealed that multiple TE treatments are more effective at maintaining stable hemoglobin levels than a single treatment. This study has several limitations. As a single-center study, the study sample may have regional and population-specific characteristics; thus, external validation studies are needed at multiple centers. Additionally, the follow-up time was relatively short; thus, longer follow-up is needed to observe the long-term effects of TE on renal function and the durability of treatment efficacy. Consideration could be given to using more rigorous study designs, such as randomized controlled trials, to better control for potential confounding factors and to validate treatment effects and renal benefits. Additionally, mechanistic research should be pursued to further explore the renal and vascular effects of TE in HAPC patients. In conclusion, our study provides new clinical evidence for the renoprotective effect of TE in HAPC patients and indicates that this protective effect is independent of improvements in hemoglobin. Therefore, these findings require external validation, and the potential underlying mechanisms need to be further explored. Furthermore, the study confirms the effectiveness of TE in HAPC patients and underscores the advantages of multiple treatments over single treatments, providing an important reference for clinical practice. Methods Study population Patients from January 2017 to December 2023 diagnosed at the Shigatse People’s Hospital was enrolled. The inclusion criteria were as follows: (1) age > 18 years; (2) diagnosis of HAPC and scheduled for TE as determined by the researcher, (3) capable of understanding the treatment purpose and signed informed consent, and (4) an estimated glomerular filtration rate (eGFR) greater than 15 ml/min/1.73 m2. The exclusion criteria were as follows: (1) inability to tolerate TE; (2) hypotension; (3) abnormally low serum calcium concentration; (4) expected survival time less than 72 h and (5) lack of data after treatment. The protocol for data analysis received approval from the ethics committee of the Shigatse People’s Hospital and was conducted in accordance with the Declaration of Helsinki. Erythrocytapheresis procedure Instruments and reagents A COBE Spectra blood cell separator (Terumo BCT, USA), disposable centrifuge-based blood component separator (Terumo BCT, USA) and ACD-A anticoagulant solution (Sichuan Nanger Bio-Pharmaceutical Co., Ltd.) were used in this study. Collection method The red blood cell single-apheresis program of the COBE Spectra blood cell separator was selected. The input parameters included sex, height, weight, and peripheral blood hematocrit, and the total circulating blood volume was calculated. The total blood volume used ranged from 1000 to 1500 mL, the blood flow rate ranged from 40 to 60 mL/min, the average ACD-A anticoagulant dose was 350 mL, and the average processing time was 79 ± 23 min. Simultaneously, an equal volume of Ringer’s solution and low-molecular-weight dextran were administered at the same rate as the red blood cell concentration process during each treatment. Anticoagulant ACD-A was used as the blood anticoagulant. Before treatment, 10 mL of 10% calcium gluconate was administered intravenously, and after treatment, an additional 10% calcium gluconate was administered based on the ACD-A dose to prevent citrate toxicity. Clinical indicators The clinical parameters included age at diagnosis, sex, race, white blood cell, red blood cell, platelet counts, hemoglobin, hematocrit levels, prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, fibrin degradation products, D-dimer levels, international normalized ratio, eGFR, uric acid, blood urea nitrogen, glucose, glycosylated hemoglobin, alanine aminotransferase, aspartate aminotransferase, total bilirubin and direct bilirubin levels before and after TE; Hyperuricemia was defined as a history of hyperuricemia or a serum uric acid level > 420 µmol/L for males and > 360 µmol/L for females26. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was used to calculate the eGFR27. Statistical methods R statistical software was used for the data analysis. All hypothesis tests were two-sided with a significance level of 0.05, and all confidence intervals were set at 95%. Descriptive statistics are presented as the means ± standard deviations (SDs) or medians (Interquartile Range, IQR) for continuous variables, depending on their normality. Categorical variables are presented as frequencies and percentages. Comparisons between groups for continuous variables were performed using t tests or Wilcoxon rank-sum tests, whereas categorical variables were compared using chi-square tests or Fisher’s exact tests. Nonparametric Wilcoxon rank-sum tests were used for ordinal data. Logistic regression models were used for propensity score matching (PSM) to ensure that covariates were balanced between the single-time and multiple-time TE treatment groups. Nearest neighbor matching was performed at a 1:1 ratio based on a propensity score within 0.05 SDs for variables including age, sex, race, and hemoglobin. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements We thank the clinicians for their contributions to these patients. We also thank the patients involved for their participation. Abbreviations Confidence interval Chronic Kidney Disease Epidemiology Collaboration Estimated glomerular filtration rate High-altitude polycythemia Interquartile range Odds ratio Propensity score matching Standard deviation Therapeutic erythrocytapheresis Author contributions Y.O., Y.Z. and H.L.contributed to data interpretation and drafting of this paper. P.D. , K.X. and K.Q. contributed to conceptualization, study design and critical revision of the draft of this work. L.M., C.Q., B.D., X.G., J.Z., P.X., Y.Z., J.Y., C.J. and F.Y. contributed to data collection. Y.O., J.L., C.J. and X.L. contributed to statistical analysis.All authors reviewed the manuscript. Funding This work was supported by the National Natural Science Foundation of China (No. 82270739, 81900656), Shanghai Shenkang Hospital Development Center Second Round of the ‘Three-Year Action Plan for Enhancing Clinical Skills and Clinical Innovation in Municipal Hospitals (2023–2025)’ Simulated RCT Study Project (SHDC2024CRI006), Shanghai “Rising Stars of Medical Talent” Youth Development Program-Youth Medical Talents-Specialty, General Practice Programs (SHWSRS(2023)_062), Shanghai Jiao Tong University “Jiao tong Star” Plan Medical Engineering Cross Research Key Project (No: YG2019QNA37), Natural Science Foundation of Shigatse (RKZ2024ZR-003(Z)), Shanghai Municipal Health Commission (General Program 202040040), Natural Science Foundation of Tibet Autonomous Region (XZ2019ZR-ZY50(Z)) and Natural Science Foundation of Tibet Autonomous Region (XZ2024ZR-ZY048(Z)). Data availability All data generated or analyzed during this study are included in this published article and its supplementary information files.Correspondence and requests for materials should be addressed to P.D., K.X. or K.Q. Declarations Ethics approval The protocol for data analysis received approval from the ethics committee of the Shigatse People’s Hospital and was conducted in accordance with the Declaration of Helsinki. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Yan Ouyang, Yinyin Zhang and Huan Li. Contributor Information Pu Bu Wang Dui, Email: Pw13908922332@163.com. Kai Xue, Email: xuekaishanghai@126.com. Kai Qing, Email: qk12217@rjh.com.cn. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All data generated or analyzed during this study are included in this published article and its supplementary information files.Correspondence and requests for materials should be addressed to P.D., K.X. or K.Q.